TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01876082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZOPANIB treatment
Description: Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Vinblastine and Methotrexate
Description: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
Study: NCT02729350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Relaxation video clip
Description: This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sickle Cell Disease Experience Discussion
Description: This intervention is a 12-minute sickle cell disease experience discussion.
Study: NCT03231423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drainage
Description: Using drain after operation
Study: NCT01736527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LE Gel
Description: Single drop of LE Gel 0.5% administered to the study eye on visit 2
Study: NCT03879135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVWF
Description: Recombinant von Willebrand factor
Study: NCT04414384

Intervention type: OTHER
Group type: OTHER
Intervention: Step Counter
Description: step counter to track steps
Study: NCT00947297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
Study: NCT03879135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVWF
Description: Recombinant von Willebrand factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant Factor VIII

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII
Description: Recombinant Factor VIII
Study: NCT00232245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil
Study: NCT01407107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.2 MG/HR
Description: 0.2mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.4 MG/HR
Description: 0.4mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.6 MG/HR
Description: 0.6mg/hr nitroglycerin transdermal patch daily. The first 3 patients will have a low dose patch applied (0.2 mg/hr) if this is well tolerated a higher dose patch (0.4mg/hr) will be used for the next 3 patients and if this is well tolerated an even higher dose patch (0.6mg/hr) will be used.
Study: NCT00836238

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Physical Function and Symptom Assessment Interviews

Intervention type: OTHER
Intervention: Physical Function Tests
Description: 3 physical function tests.
Study: NCT01248130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 Fatty Acid
Description: Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
Study: NCT04645342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baylis Versacross RF wire
Description: Baylis Versacross radiofrequency wire is used for transseptal puncture during cardiac ablation procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baylis RF needle
Description: Baylis radiofrequency needle is used for transseptal puncture during cardiac ablation procedure.
Study: NCT03465072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 8 weeks, 3 times per week, 30-40 minutes
Study: NCT01757873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03427827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
Study: NCT01410565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apaziquone
Description: Apaziquone 4 mg in 40 mL diluent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Double Blind Phase
Study: NCT05097066

Intervention type: PROCEDURE
Intervention: Neurosurgical procedure
Description: Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.

Intervention type: PROCEDURE
Intervention: Neurosurgical procedure
Description: Any neurosurgical procedure in the National Neurosurgical Audit Programme (NNAP) Coding Framework of neurosurgical procedures.
Study: NCT01940276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT01598740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLP
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLP
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: oral administration
Study: NCT04060979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide given intermittently via inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide given intermittently via inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Supportive treatment
Description: Standard Supportive treatment (including oxygen)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Supportive treatment
Description: Standard Supportive treatment (including oxygen)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Supportive treatment
Description: Standard Supportive treatment (including oxygen)
Study: NCT03587740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
Study: NCT03120065

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Dose Monitoring (MEMS)
Description: The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
Study: NCT06363084

Intervention type: DRUG
Intervention: Nimotuzumab
Description: Nimotuzumab (400mg) was given weekly
Study: NCT00864474

Intervention type: DRUG
Intervention: CELSENTRI® Tablets
Description: CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food.
Study: NCT01945385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video intervention
Description: Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
Study: NCT04666870

Intervention type: OTHER
Intervention: myopia or not myopia
Description: visual acuity, IOL master biometry, the anterior segment with slit lamp, dilated fundus examination and refraction.
Study: NCT02804503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie Labels
Description: Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Labels
Description: Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Labels
Description: Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
Study: NCT02851108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 50 patients will receive methylene blue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 50 patients will receive primaquine
Study: NCT00008346

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full Field Digital Mammography
Description: Radiologic test to screen women for Breast cancer using digital detectors

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Full Field Digital Mammography
Description: Radiologic test to screen women for Breast cancer using digital detectors

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Screen Film Mammography
Description: Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Screen Film Mammography
Description: Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
Study: NCT04524403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorlilant
Description: Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorlilant
Description: Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for once-daily oral dosing
Study: NCT03063359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl + Oral Placebo
Description: Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
Study: NCT03063359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Morphine + Intranasal Placebo
Description: Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
Study: NCT00283660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 mg zinc oxide
Description: 10 mg zinc oxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken five days a week for six months.
Study: NCT03375346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
Study: NCT03905551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Dialysis
Description: Dialysate temperature reduced to 35oC for a period of 7 months.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Typical Dialysis
Description: Dialysate temperature is set at 37oC for a period of 7 months
Study: NCT00029107

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: anti-CD20 monoclonal antibody

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: anti-CD20 monoclonal antibody
Study: NCT04208165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided nerve block PVB
Description: Thoracic paravertebral block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
Study: NCT03905551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic Intradialytic exercise training

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Aerobic Intradialytic exercise training
Study: NCT04208165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided nerve block TAB
Description: Transverse abdominis plane block guided by ultrasound device which allows visualizing the surrounding anatomy and placement of the needle at the target location in real time.
Study: NCT05937230

Intervention type: DEVICE
Intervention: Drug-coated balloon
Description: Paclitaxel is a pharmacologically active substance for anti-neointima.

Intervention type: DEVICE
Intervention: Drug-eluting stents
Description: Drug-eluting stent is composed of a metal stent, primer, and drug coating.
Study: NCT02776215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: Melatonin receptor agonist
Study: NCT00557700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of inhaled tiotropium bromide
Description: Administration of inhaled tiotropium bromide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: Administration of placebo
Study: NCT02894060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood tests
Description: Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)
Study: NCT04362761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT02922439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention
Description: The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
Study: NCT00574405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])
Description: MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSII (Animas Corporation insulin pump, model IR 1200)
Description: CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
Study: NCT02828839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access needle
Description: The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
Study: NCT02553681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: roflufocon D contact lenses
Description: HPT treated rigid contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RGP contact lenses made from roflufocon D
Study: NCT00004123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride (DOX)
Description: Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
Study: NCT02449356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prone position endotracheal tube(PPT)
Description: some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
Study: NCT00978731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~* 5 days on, 2 days off~* 6 days on, 1 day off~* Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study
Study: NCT02460640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tap block
Description: intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous Patient controlled analgesia
Description: intravenous patient-controlled analgesia with morphine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous Patient controlled analgesia
Description: intravenous patient-controlled analgesia with morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT02258152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN120
Description: SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD
Study: NCT02010424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: standard IVF protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primo Vision embryo culture dish (CE labeled, Vitrolife)
Study: NCT02616250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.33% gel (Br)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD07805/47 (Br) placebo gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CD07805/47 (Br) placebo gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream (IVM)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CD5024 (IVM) placebo cream
Study: NCT00794872

Intervention type: OTHER
Intervention: blood sampling

Intervention type: OTHER
Intervention: blood sampling

Intervention type: OTHER
Intervention: blood sampling
Study: NCT00827372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be administered at a starting dose of 800 mg orally once each day.
Study: NCT00004123

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Description: Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: 5 days a week for 4 weeks
Study: NCT04635631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: Talazoparib will be administered orally on a continuous basis. Each cycle will consist of 28 days.
Study: NCT03976921

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Integration of CCTA with stress CTP when indicated
Description: When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care approach
Description: (a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.